Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Observational 8Interventional 3

Sponsor

Cancer Type

Other neoplasm 4Other hematologic neoplasm 4Myeloid 4Lymphoid 4Gastrointestinal 3Breast 3Plasma cell 1Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Patient Reported Outcome Measures × Breast × Clear all
NCT04272801 2025-10-22

POWER

University of Virginia

Phase 2 Active not recruiting
84 enrolled 9 charts
Breast

Breast Neoplasms

NCT03958136 2025-08-17

EPICURE_SEIN

Institut Cancerologie de l'Ouest

Phase NA Active not recruiting
289 enrolled
Breast

Breast Neoplasms

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated
1 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡